Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Cash & Equivalents (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Cash & Equivalents for 2 consecutive years, with $175.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 128.07% to $175.4 million in Q4 2025 year-over-year; TTM through Oct 2025 was $175.4 million, a 128.07% increase, with the full-year FY2025 number at $237.6 million, up 2780.29% from a year prior.
  • Cash & Equivalents was $175.4 million for Q4 2025 at Kestra Medical Technologies, down from $201.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $237.6 million in Q2 2025 to a low of $8.2 million in Q2 2024.